Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company has reached a settlement tied to Chantix, a smoking-cessation medicine, with payouts potentially available to eligible claimants. A notice points readers to the claim process and filing timeframe.
THE APEX TIMES
THE APEX TIMES
Pfizer reported a second-quarter beat and lifted its 2026 revenue outlook, sending shares up sharply. The backdrop remains challenging, with declining COVID-19 revenue and pressure from patent-related losses.
THE APEX TIMES
The new report, distributed via a GlobeNewswire announcement syndicated on Yahoo Finance, examines the global influenza vaccine market and includes company profiles of Pfizer, GSK, Sanofi and Moderna.
THE APEX TIMES
A market-focused post following second-quarter results frames the choice for income-seeking investors as a trade-off between Pfizer’s shareholder payout profile and Merck’s efforts to fund the next growth phase through acquisitions or licensing-style investments.
THE APEX TIMES
A Yahoo Finance report says Pfizer’s second-quarter update included higher full-year revenue guidance and steady non-COVID product performance, even as it reported a net loss and sizable non-cash impairments. The article frames the move as a potential valuation catch-up for the company’s earnings expectations.
THE APEX TIMES
A market-focused roundup tied Gilead’s “uncertain” near-term outlook, Merck’s PCSK9 launch risk, and a potential trial readout that could reshape Pfizer’s trajectory in the coming quarters.
THE APEX TIMES
In a recent earnings call recap published by Yahoo Finance, Pfizer pointed to improving momentum outside of COVID-19, deeper planned cost actions, and upcoming pipeline catalysts as key offsets to a softer COVID backdrop.
THE APEX TIMES
Pfizer reported an earnings and outlook update that included higher savings targets and revenue guidance, but trading sentiment remained cautious ahead of the company’s transition away from expiring patents and toward later-stage product growth.
THE APEX TIMES
The drugmaker posted second-quarter revenue of $15 billion and adjusted diluted earnings per share of $0.77, saying both figures beat its own forecast levels.
